Barclays
RXRX icon

Barclays’s Recursion Pharmaceuticals RXRX Stock Holding History

Barclays’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Sell
118,060
-35,211
-23% -$117K ﹤0.01% 3310
2026
Q1 		$471K Sell
153,271
-1,315,991
-90% -$5.09M ﹤0.01% 3223
2025
Q4 		$6.01M Sell
1,469,262
-80,964
-5% -$401K ﹤0.01% 2068
2025
Q3 		$7.57M Buy
1,550,226
+385,537
+33% +$2.02M ﹤0.01% 1883
2025
Q2 		$5.89M Buy
1,164,689
+573,683
+97% +$2.82M ﹤0.01% 1981
2025
Q1 		$3.13M Sell
591,006
-42,119
-7% -$307K ﹤0.01% 2287
2024
Q4 		$4.28M Sell
633,125
-64,307
-9% -$432K ﹤0.01% 2296
2024
Q3 		$4.6M Buy
697,432
+304,278
+77% +$2.18M ﹤0.01% 2164
2024
Q2 		$2.95M Buy
393,154
+78,853
+25% +$688K ﹤0.01% 1866
2024
Q1 		$3.13M Sell
314,301
-282,257
-47% -$3.14M ﹤0.01% 2189
2023
Q4 		$5.88M Buy
596,558
+38,787
+7% +$277K ﹤0.01% 1953
2023
Q3 		$4.27M Buy
557,771
+369,103
+196% +$3.68M ﹤0.01% 1412
2023
Q2 		$1.41M Buy
188,668
+446
+0.2% +$3.12K ﹤0.01% 2099
2023
Q1 		$1.26M Sell
188,222
-108,378
-37% -$860K ﹤0.01% 2561
2022
Q4 		$2.29M Buy
296,600
+184,366
+164% +$1.81M ﹤0.01% 2180
2022
Q3 		$1.2M Buy
112,234
+91,762
+448% +$929K ﹤0.01% 2103
2022
Q2 		$166K Sell
20,472
-2,556
-11% -$17.1K ﹤0.01% 3540
2022
Q1 		$165K Buy
+23,028
New +$245K ﹤0.01% 3538

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays's RXRX Position: Q2 2026 in Review

Barclays reduced its Recursion Pharmaceuticals (RXRX) stake by 23% in Q2 2026, selling an estimated $117K and leaving 118,060 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #3310.

Barclays first reported a position in RXRX in Q1 2022 and has held it in 18 quarters since. The position peaked at $7.57M in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Barclays held 118,060 shares of Recursion Pharmaceuticals worth $433K as of Q2 2026.
  • Barclays sold 35,211 Recursion Pharmaceuticals shares in Q2 2026, an estimated $117K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3310 holding.
  • Barclays first reported a position in Recursion Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Recursion Pharmaceuticals position peaked at $7.57M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.